Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effecten van een Online Ondersteuningsprogramma voor Hartstilstandoverlevenden (CARDIS)

9 november 2026 bijgewerkt door: Ingela Thylén, Linkoeping University

Effecten van een Online Ondersteuningsprogramma voor Hartstilstand Overlevers: Een Gerandomiseerde Gecontroleerde Studie met Procesevaluatie (De CARDIS Studie)

The overall goal of this clinical trial is to learn if a web-based support programme can improve wellbeing in cardiac arrest survivors by helping them manage emotional, cognitive, and physical challenges. The study also explores how the programme is used and experienced in practice.

The main questions it aims to answer are:

  • Can access to a web-based support programme improve overall wellbeing in cardiac arrest survivors?
  • Can it also enhance quality of life, cognitive function, life satisfaction, and sleep, while reducing anxiety, depression, post-traumatic stress, and fatigue? Researchers will compare cardiac arrest survivors who receive a web-based support programme in addition to standard care with those who receive standard care alone, to see if the programme improves wellbeing and other health outcomes. After the study, the control group will also gain access to the programme.

Participants will:

  • Be asked to complete online questionnaires at three time points: at the start of the study, after 3 months, and after 6 months.
  • Be encouraged to use a web-based support programme for 3 months, with unlimited access, at their own pace and according to their individual needs (intervention group only).

Studie Overzicht

Toestand

Aanmelden op uitnodiging

Gedetailleerde beschrijving

Cardiac arrest is a serious public health issue, affecting around 13,000 people annually in Sweden. Survivors often face long-term physical, cognitive, and emotional challenges, including anxiety, depression, fatigue, sleep disturbances, and post-traumatic stress. These difficulties can significantly impact daily life, and many survivors struggle to return to work or previous routines.

Although guidelines recommend follow-up within 1-3 months after hospital discharge, support is often fragmented and varies across regions. Survivors frequently report limited access to reliable information and emotional support. Research has shown that structured education and rehabilitation are essential for both survivors and their families, yet current care models rarely address these needs in a comprehensive way.

To help fill this gap, a web-based support programme was co-created in 2024-2025 by researchers, healthcare professionals, cardiac arrest survivors, and patient organizations. The programme includes educational modules, patient and family stories, videos, practical exercises, and tools for self-management and personal recovery planning. It also features a moderated chat forum for peer support. A feasibility study showed that the programme was easy to use and perceived as relevant and helpful.

The study begins with a pilot phase (n=10) to test study procedures, followed by a randomized controlled trial (RCT) with 120 participants across six Swedish regions. Participants are recruited during routine follow-up visit one month after discharge. All participants receive standard care. Those randomized to the intervention group gain access to the digital support programme for 12 weeks. The control group receives standard care and gains access to the programme after study completion.

Consent and data collection are handled digitally. Participants are asked to complete online surveys at baseline, 3 months, and 6 months. These surveys cover wellbeing, quality of life, sleep, fatigue, emotional health, and cognitive function. The study also collects usage data from the programme to understand how participants engage with the content. No physical tests or extra clinic visits are required.

The study aims to generate new knowledge about how digital tools can support recovery after cardiac arrest, improve wellbeing, and reduce healthcare burden by offering accessible, person-centered rehabilitation.

Studietype

Ingrijpend

Inschrijving (Geschat)

120

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

      • Gothenburg, Zweden
        • Sahlgrenska Universitetssjukhuset
      • Gothenburg, Zweden
        • Östra sjukhuset
      • Helsingborg, Zweden
        • Helsingborgs lasarett
      • Kalmar, Zweden
        • Länssjukhuset
      • Linköping, Zweden
        • Universitetssjukhuset
      • Lund, Zweden
        • Skånes universitetssjukhus
      • Motala, Zweden
        • Lasarettet i Motala
      • Norrköping, Zweden
        • Vrinnevisjukhuset
      • Stockholm, Zweden
        • Capio S:t Görans sjukhus
      • Stockholm, Zweden
        • Karolinska universitetssjukhuset
      • Västerås, Zweden
        • Västmanlands sjukhus Västerås

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Age 18 years or older
  • Survival of a cardiac arrest 1 to 3 months prior to enrollment
  • Access to a mobile phone, tablet, or computer with internet connection

Exclusion Criteria:

  • Insufficient language or cognitive ability to engage with a digital intervention and complete questionnaires in Swedish
  • Participation in another study involving the collection of patient-reported outcome measures (PROMs)

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Enkel

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Webgebaseerd Ondersteuningsprogramma voor Hartstilstandoverlevenden

The intervention consists of a web-based support programme designed for individuals recovering from cardiac arrest. Participants in the intervention group receive access to the programme for 12 weeks. The programme includes educational modules, patient and family stories, videos, practical exercises (e.g., breathing techniques, fatigue management), tools for personal recovery planning, and a moderated chat forum for peer support. Participants can access the content at their own pace and according to their individual needs. The programme is delivered entirely online and does not require any physical visits or clinical procedures.

Geen tussenkomst: Waitlist Control (Standard Care + Delayed Access)

Participants in this arm receive standard follow-up care according to national guidelines. They do not have access to the digital support programme during the study period. However, they are placed on a waitlist and are offered access to the programme after study completion.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Overall Wellbeing at 3 months.
Tijdsspanne: From baseline to 3 months after enrollment.

The Questionnaire on Well-Being is a tool designed to capture subjective well-being. It consists of 18 questions, each rated from 0 to 4, which are added together to give a total score between 0 and 72. Higher scores reflect greater perceived well-being, while scores below 50 have been linked to significant psychological distress.

From baseline to 3 months after enrollment.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Change from Baseline in Quality of Life at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Quality of Life (EuroQol Five-Dimension Five-Level questionnaire, EQ-5D-5L).

Score range: 0 to 1 (index value). Higher scores indicate better quality of life.

Change from baseline in Quality of Life (EuroQol Visual Analogue Scale). Score range: 0 to 100. Higher scores indicate better self-rated health.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Life Satisfaction at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Life Satisfaction (Life Satisfaction Questionnaire, LiSat-11) at 3 and 6 months.

Score range: 11 to 66. Higher scores indicate greater life satisfaction. Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Anxiety at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Anxiety (Generalised Anxiety Disorder 7-item scale, GAD-7) at 3 and 6 months.

Score range: 0 to 21. Higher scores indicate more severe anxiety symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Depression at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Depression (Patient Health Questionnaire 9-item scale, PHQ-9) at 3 and 6 months. Score range: 0 to 27. Higher scores indicate more severe depressive symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Post-Traumatic Stress at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Post-Traumatic Stress (Impact of Event Scale - Revised, IES-R) at 3 and 6 months. Score range: 0 to 88. Higher scores indicate more severe post-traumatic stress symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Fatigue at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Fatigue (Modified Fatigue Impact Scale, MFIS-21) at 3 and 6 months. Score range: 0 to 84. Higher scores indicate greater impact of fatigue.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Sleep at 3 and 6 months.
Tijdsspanne: From baseline to 3 and 6 months after enrollment.

Change from baseline in Sleep (Minimal Insomnia Symptom Scale, MISS) at 3 and 6 months. Score range: 0 to 12. Higher scores indicate more severe insomnia symptoms.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 and 6 months after enrollment.
Change from baseline in Cognitive Function at 3 and 6 months.
Tijdsspanne: From baseline to 3 months after enrollment.

Change from baseline in Cognitive Function (single-item question on perceived cognitive difficulties) at 3 and 6 months. Score range: 1 to 5. Higher scores indicate greater perceived cognitive impairment.

Outcomes will be analyzed both as change from baseline to each time point (3 and 6 months), and as within-subject change between the 3- and 6-months assessments to evaluate sustained or delayed effects of the intervention.

From baseline to 3 months after enrollment.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

20 november 2025

Primaire voltooiing (Geschat)

31 mei 2028

Studie voltooiing (Geschat)

31 augustus 2028

Studieregistratiedata

Eerst ingediend

14 november 2025

Eerst ingediend dat voldeed aan de QC-criteria

18 november 2025

Eerst geplaatst (Werkelijk)

21 november 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

De-identified individual participant data (IPD) will be made available to members of the research team after the principal investigator has completed blinded analyses of the primary and secondary outcomes. Data will be stored securely and access will be restricted to authorized collaborators under data use agreements.

IPD-tijdsbestek voor delen

Beginning after completion of the blinded primary and secondary outcome analyses by the principal investigator, with no defined end date.

IPD-toegangscriteria voor delen

Access to de-identified individual participant data (IPD) will be granted to members of the research team after completion of the blinded analysis of primary and secondary outcomes by the principal investigator. Each researcher must submit a brief description of the planned analyses and sign a data use agreement outlining responsibilities for data handling, confidentiality, and publication ethics. Access requests will be reviewed and approved by the principal investigator.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ANALYTIC_CODE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren